If you are found to be eligible to take part in this study, you will receive tremelimumab by vein over about 1 hour and MEDI4736 by vein over about 4 hours during Week 11. After Week 11, you will receive MEDI4736 alone by vein over about 1 hour during Weeks 21, 25, 29, and 33.